Cardiology in review
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.
Ashwin A Pillai, Ashish M Sharma, Hussein Krayem, William H Frishman, Wilbert S Aronow
Published: 202510.1097/CRD.0000000000001139
Abstract
The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of…
Preview only. Read the full abstract at the source